NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations
Executive Summary
New cancer immunotherapies are doing well in lung cancer, with Merck's Keytruda picking up share in the first-line setting and Roche's Tecentriq in second-line. Bristol-Myers Squibb is banking on combo therapy to restore its momentum.